This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic Hyperplasia (BPH). The study consists of a screening phase, treatment, followed by follow-up visits at 1 week, 4 weeks, 3 months, 6 months, and 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
66
Treatment of BPH with Greenlight XPS laser
treatment of BPH with BiVAP Saline Vaporization
Brooklyn Urology Research Group
Brooklyn, New York, United States
Change From Baseline in American Urological Association Symptom Score
The American Urological Association Symptom Score range is 0-35 with 35 being the most severe urinary symptoms
Time frame: Baseline and 12 months
Change From Baseline to 12 Months in Maximum Urinary Flow Rate (Qmax)
maximum urinary flow rate was measures using uroflow device
Time frame: baseline and 12 months
Change From Baseline to 12 Months in Post Void Residual Volume
post void residual was measured using a bladder scan device
Time frame: baseline and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.